Constructing longitudinal disease progression curves using sparse, short‐term individual data with an application to Alzheimer's disease

In epidemiology, cohort studies utilised to monitor and assess disease status and progression often result in short-term and sparse follow-up data. Thus, gaining an understanding of the full-term disease pathogenesis can be difficult, requiring shorter-term data from many individuals to be collated. We investigate and evaluate methods to construct and quantify the underlying long-term longitudinal trajectories for disease markers using short-term follow-up data, specifically applied to Alzheimer's disease. We generate individuals' follow-up data to investigate approaches to this problem adopting a four-step modelling approach that (i) determines individual slopes and anchor points for their short-term trajectory, (ii) fits polynomials to these slopes and anchor points, (iii) integrates the reciprocated polynomials and (iv) inverts the resulting curve providing an estimate of the underlying longitudinal trajectory. To alleviate the potential problem of roots of polynomials falling into the region over which we integrate, we propose the use of non-negative polynomials in Step 2. We demonstrate that our approach can construct underlying sigmoidal trajectories from individuals' sparse, short-term follow-up data. Furthermore, to determine an optimal methodology, we consider variations to our modelling approach including contrasting linear mixed effects regression to linear regression in Step 1 and investigating different orders of polynomials in Step 2. Cubic order polynomials provided more accurate results, and there were negligible differences between regression methodologies. We use bootstrap confidence intervals to quantify the variability in our estimates of the underlying longitudinal trajectory and apply these methods to data from the Alzheimer's Disease Neuroimaging Initiative to demonstrate their practical use. Copyright © 2017 John Wiley & Sons, Ltd.

[1]  Ana Ivelisse Avilés,et al.  Linear Mixed Models for Longitudinal Data , 2001, Technometrics.

[2]  M. Prince,et al.  World Alzheimer Report 2015 - The Global Impact of Dementia: An analysis of prevalence, incidence, cost and trends , 2015 .

[3]  Harvey Goldstein,et al.  Handbook of multilevel analysis , 2008 .

[4]  J. Morris,et al.  Clinical core of the Alzheimer's disease neuroimaging initiative: Progress and plans , 2010, Alzheimer's & Dementia.

[5]  P. Gottschalk,et al.  The five-parameter logistic: a characterization and comparison with the four-parameter logistic. , 2005, Analytical biochemistry.

[6]  C. Jack,et al.  Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers , 2013, The Lancet Neurology.

[7]  C. Jack,et al.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.

[8]  C. Rowe,et al.  The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease , 2009, International Psychogeriatrics.

[9]  The Neuropathology of Alzheimer’s Disease , 2019, Alzheimer’s Disease.

[10]  Mark E. Schmidt,et al.  The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception , 2012, Alzheimer's & Dementia.

[11]  Colin L Masters,et al.  Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics , 2006, Journal of neurochemistry.

[12]  Peter J Gianaros,et al.  Longitudinal assessment of neuroimaging and clinical markers in autosomal dominant Alzheimer's disease: a prospective cohort study , 2015, The Lancet Neurology.

[13]  Bootstrapping Robust Estimates for Clustered Data , 2010 .

[14]  Samuel Müller,et al.  Fast and flexible methods for monotone polynomial fitting , 2016 .

[15]  G. B. Frisoni,et al.  The dynamics of Alzheimer's disease biomarkers in the Alzheimer's Disease Neuroimaging Initiative cohort , 2010, Neurobiology of Aging.

[16]  C. Masters,et al.  Neurodegenerative Diseases: The neuropathology of Alzheimer's disease in the year 2005 , 2005 .

[17]  M. Mintun,et al.  Performance Characteristics of Amyloid PET with Florbetapir F 18 in Patients with Alzheimer's Disease and Cognitively Normal Subjects , 2012, The Journal of Nuclear Medicine.

[18]  M. Kenward,et al.  An Introduction to the Bootstrap , 2007 .

[19]  Nick C Fox,et al.  Clinical and biomarker changes in dominantly inherited Alzheimer's disease. , 2012, The New England journal of medicine.

[20]  France Mentré,et al.  A comparison of bootstrap approaches for estimating uncertainty of parameters in linear mixed‐effects models , 2013, Pharmaceutical statistics.

[21]  G. Molenberghs Applied Longitudinal Analysis , 2005 .

[22]  Matthew L Senjem,et al.  Shapes of the trajectories of 5 major biomarkers of Alzheimer disease. , 2012, Archives of neurology.

[23]  Robert Chambers,et al.  A Random Effect Block Bootstrap for Clustered Data , 2013 .

[24]  C. Field,et al.  Bootstrapping clustered data , 2007 .

[25]  Rudi Verbeeck,et al.  Quantifying the pathophysiological timeline of Alzheimer's disease. , 2011, Journal of Alzheimer's disease : JAD.

[26]  V. Narayan,et al.  Disease progression model for Clinical Dementia Rating–Sum of Boxes in mild cognitive impairment and Alzheimer’s subjects from the Alzheimer’s Disease Neuroimaging Initiative , 2014, Neuropsychiatric disease and treatment.

[27]  M. Weiner,et al.  The dynamics of cortical and hippocampal atrophy in Alzheimer disease. , 2011, Archives of neurology.

[28]  M. Sherman,et al.  A comparison between bootstrap methods and generalized estimating equations for correlated outcomes in generalized linear models , 1997 .

[29]  S. Leurgans,et al.  Sigmoidal mixed models for longitudinal data , 2018, Statistical methods in medical research.

[30]  D. Selkoe Alzheimer's disease: genes, proteins, and therapy. , 2001, Physiological reviews.

[31]  Mark E. Schmidt,et al.  The Alzheimer’s Disease Neuroimaging Initiative: A review of papers published since its inception , 2012, Alzheimer's & Dementia.

[32]  P. Scheltens,et al.  Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria , 2007, The Lancet Neurology.

[33]  Keith A. Johnson,et al.  Amyloid-β deposition in mild cognitive impairment is associated with increased hippocampal activity, atrophy and clinical progression. , 2015, Brain : a journal of neurology.

[34]  C. Rowe,et al.  Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study , 2013, The Lancet Neurology.

[35]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[36]  Louis Brickman On Nonnegative Polynomials , 1962 .